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Renal Artery Stenting Following
Unsuccessful Balloon Angioplasty
As an interventional cardiologist I read with great interest the
Rocha-Singh et al. (1) paper regarding renal artery stenosis and
revascularization. I think an excellent job was done in delineating
the usual indications. However, new ideas have recently surfaced
regarding how to determine the significance of a lesion, and more
information is now available regarding the physiology of a signif-
icant renal artery stenosis.
The radiologist and vascular surgeon, in general, are often not
conversant with the adverse effects of a hyperrenin state, congestive
heart failure, unstable angina, and progression of atherosclerosis.
Unfortunately, many well-known experts, in the face of a hemo-
dynamically significant lesion, have over the years, advocated
delaying stenting until creatinine is elevated. However, when
creatinine is 2 mg/dl, (12.5% of study patients) mortality has
been shown to be grossly increased in studies where patients are
followed over a four-year period (2,3). Half of renal function may
be lost before creatinine is elevated, and there should be an obvious
attempt to find these patients before renal function has deterio-
rated and mortality and morbidity have escalated (4). Renal artery
Doppler, renal scan, and creatinine clearance will give subtle clues
to early loss of kidney function, and beta-natriuretic peptide may
be elevated.
The “unobvious” patients needing revascularization may be the
patients with elevated creatinine without hypertension, often in the
face of peripheral vascular disease and coronary disease; unilateral
kidney shrinkage without significant hypertension; or sudden
significant increase in blood pressure. The number of medications
should be removed as a parameter for interventions if the patient
is treated with clonidine, labetalol, or minoxidil, as moderate doses
of these drugs may be equivalent to multiple medications.
Moreover, it needs to be emphasized that the significance of the
lesion is often much greater than its angiographic appearance and
can be confirmed by flow-wire measurement of pressure gradients
and fractional flow reserve (FFR) (5), with these measurements
perhaps supplanting 4F catheter gradient measurements. (French
size of catheter used for gradient measurement is not discussed in
the study.) Then there is the asymptomatic patient with normal
creatinine, with a high-grade renal artery stenosis and an extremely
high gradient. Obviously the patient with a hyperrenin state will
undergo significant progression of diffuse atherosclerosis and
progression of arteriolar nephrosclerosis in the contralateral kidney
(6). This patient should be revascularized.
These comments should be read in context, as the ASPIRE-2
study was performed 8 to 10 years ago. It is hoped that new studies
regarding further research into FFR with varying degrees of renal
stenosis, cytokine release in the presence of renal artery stenosis,
and the effects of progression of diffuse atherosclerosis, congestive
heart failure, and unstable angina will be delineated.
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